Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A-205804 is a potent and selective small molecule inhibitor of E-selectin and intercellular adhesion molecule-1 (ICAM-1) expression.[1][3] The compound functions as an inhibitor of cell adhesion molecules that mediate endothelial-leukocyte interactions essential in inflammatory responses.[1] Mechanistically, A-205804 translocates to the nucleus and binds non-covalently to large molecular targets (>650 kDa).[1] It is orally bioavailable and serves as a research tool for studying inflammatory processes and adhesion-associated diseases, including potential applications in cancer research and neuropathic pain models.[2][4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on A-205804.